Interferon alfa-2b in the management of recurrent conjunctival papillomatosis.
Indian J Ophthalmol, 2016 Singh M, Gautam N, Gupta A, Kaur M.
europepmc +1 more source
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update [PDF]
, 2018 et al,, Picus, Joel
core +1 more source
Neutrophil-to-lymphocyte ratio half reduction as a surrogate of molecular response in polycythemia vera treated with ropeginterferon alfa-2b. [PDF]
Ther Adv HematolYoon SY +14 more
europepmc +1 more source
Efficacy and safety of ropeginterferon alfa-2b in the treatment of polycythemia vera: a systematic review with single arm meta-analysis. [PDF]
Ann HematolNada EA +10 more
europepmc +1 more source
Toward new therapy end points in polycythemia vera: targeting clonal and inflammatory pathways. [PDF]
Blood AdvBarbui T, Scandura JM.
europepmc +1 more source
Related searches:
Interferon Alfa for Macular Degeneration
Annals of Pharmacotherapy, 1996Clinical studies demonstrate that interferon alfa has little benefit in treating CNV secondary to macular degeneration. However, it may be useful in the treatment of choroidal and retinal hemangiomas, diabetic and post-vein occlusion retinopathy, and retinopathy of prematurity.
S L, Williford, T, King
openaire +2 more sources
Scleromyxedema: Treatment with interferon alfa
Journal of the American Academy of Dermatology, 1999Scleromyxedema is a variant of papular mucinosis characterized by fibroblast proliferation and mucin deposition in the dermis. Historically, it has been very difficult to treat and can cause significant morbidity and mortality with systemic involvement.
J A, Tschen, J R, Chang
openaire +2 more sources